Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5608_Библиотеки_им_академика_М_И_Перельмана.pdf
210
Fasihuddin M, You W, Xie Z, Zhao Y, Jiang Z, Zhao G, Zhang Y, Mahmoud S, ElTantawy I,
Xiao P, Koshy A, Zaher WA, Wang H, Duan K, Pan A, Yang X (2021) Effect of 2 inactivated
SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical
trial. JAMA 326:35–45. https://doi.org/10.1001/jama.2021.8565
39. Tian J-H, Patel N, Haupt R, Zhou H, Weston S, Hammond H, Logue J, Portnoff AD, Norton
J, Guebre-Xabier M, Zhou B, Jacobson K, Maciejewski S, Khatoon R, Wisniewska M,
Moftt W, Kluepfel-Stahl S, Ekechukwu B, Papin J, Boddapati S, Jason Wong C, Piedra PA,
Frieman MB, Massare MJ, Fries L, Bengtsson KL, Stertman L, Ellingsworth L, Glenn G,
Smith G (2021) SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun 12:372. https://doi.org/10.1038/
s41467- 020- 20653- 8
40. Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S,
Zhou H, Smith G, Patel N, Frieman MB, Haupt RE, Logue J, McGrath M, Weston S, Piedra
PA, Desai C, Callahan K, Lewis M, Price-Abbott P, Formica N, Shinde V, Fries L, Lickliter
JD, Grifn P, Wilkinson B, Glenn GM (2020) Phase 1–2 trial of a SARS-CoV-2 recombinant
spike protein nanoparticle vaccine. N Engl J Med 383:2320–2332. https://doi.org/10.1056/
NEJMoa2026920
41. Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, Harper WL,
Duncanson DM, McArthur MA, Florescu DF, McClelland RS, Garcia-Fragoso V, Riesenberg
RA, Musante DB, Fried DL, Sarstein BE, McKenzie M, Jeanfreau RJ, Kingsley JK,
Henderson JA, Lane DC, Ruíz-Palacios GM, Corey L, Neuzil KM, Coombs RW, Greninger
AL, Hutter J, Ake JA, Smith K, Woo W, Cho I, Glenn GM, Dubovsky F (2021) Efcacy
and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med
386:531–543. https://doi.org/10.1056/NEJMoa2116185
42. Ward BJ, Gobeil P, Séguin A, Atkins J, Boulay I, Charbonneau P-Y, Couture M, D’Aoust
M-A, Dhaliwall J, Finkle C, Hager K, Mahmood A, Makarkov A, Cheng MP, Pillet S,
Schimke P, St-Martin S, Trépanier S, Landry N (2021) Phase 1 randomized trial of a plantderived virus-like particle vaccine for COVID-19. Nat Med 27:1071–1078. https://doi.
org/10.1038/s41591- 021- 01370- 1
43. Hager KJ, Pérez Marc G, Gobeil P, Diaz RS, Heizer G, Llapur C, Makarkov AI, Vasconcellos
E, Pillet S, Riera F, Saxena P, Geller Wolff P, Bhutada K, Wallace G, Aazami H, Jones CE,
Polack FP, Ferrara L, Atkins J, Boulay I, Dhaliwall J, Charland N, Couture MMJ, JiangWright J, Landry N, Lapointe S, Lorin A, Mahmood A, Moulton LH, Pahmer E, Parent J,
Séguin A, Tran L, Breuer T, Ceregido M-A, Koutsoukos M, Roman F, Namba J, D’Aoust
M-A, Trepanier S, Kimura Y, Ward BJ (2022) Efcacy and safety of a recombinant plantbased adjuvanted COVID-19 vaccine. N Engl J Med 386:2084–2096. https://doi.org/10.1056/
NEJMoa2201300
44. Pillet S, Arunachalam PS, Andreani G, Golden N, Fontenot J, Aye PP, Röltgen K, Lehmicke
G, Gobeil P, Dubé C, Trépanier S, Charland N, D’Aoust M-A, Russell-Lodrigue K, Monjure
C, Blair RV, Boyd SD, Bohm RP, Rappaport J, Villinger F, Landry N, Pulendran B, Ward
BJ (2022) Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for
COVID-19in nonhuman primates. Cell Mol Immunol 19:222–233. https://doi.org/10.1038/
s41423- 021- 00809- 2
45. Ryzhikov AB, Ryzhikov EА, Bogryantseva MP, Danilenko ED, Imatdinov IR, Nechaeva
EA, Pyankov OV, Pyankova OG, Susloparov IM, Taranov OS, Gudymo AS, Danilchenko
NV, Sleptsova ES, Bodnev SA, Onkhonova GS, Petrov VN, Moiseeva AA, Torzhkova
PY, Pyankov SA, Tregubchak TV, Antonets DV, Gavrilova EV, Maksyutov RA (2021)
Immunogenicity and protectivity of the peptide vaccine against SARS-CoV-2. Ann Rus Acad
Med Sci 76:5–19. https://doi.org/10.15690/vramn1528
46. Ryzhikov AB, Ryzhikov ЕА, Bogryantseva MP, Usova SV, Danilenko ED, Nechaeva EA,
Pyankov OV, Pyankova OG, Gudymo AS, Bodnev SA, Onkhonova GS, Sleptsova ES,
Kuzubov VI, Ryndyuk NN, Ginko ZI, Petrov VN, Moiseeva AA, Torzhkova PY, Pyankov
J. A. S. Romine etal.
8 COVID-19 Vaccine Manufacturing Processes: Making the Molecules to Solve…
SA, Tregubchak TV, Antonec DV, Gavrilova EV, Maksyutov RA (2021) A single blind,
placebo- controlled randomized study of the safety, reactogenicity and immunogenicity of the
“EpiVacCorona” vaccine for the prevention of COVID-19, in volunteers aged 18–60 years
(phase I–II). Rus J Infect Immun 11:283–296. https://doi.org/10.15789/2220- 7619- asb- 1699
47. Pious N, Ingole SD (2020) Race for COVID-19 vaccine. Trends Biomater Artif Organs
34:62–65
48. Thorn CR, Sharma D, Combs R, Bhujbal S, Romine J, Zheng X, Sunasara K, Badkar A
(2022) The journey of a lifetime—development of Pzer’s COVID-19 vaccine. Curr Opin
Biotechnol:102803. https://doi.org/10.1016/j.copbio.2022.102803
49. Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, Aroca Martinez GJ, Bonten M, Chandler
R, Corral G, De Block EJL, Ecker L, Gabor JJ, Garcia Lopez CA, Gonzales L, Granados
González MA, Gorini N, Grobusch MP, Hrabar AD, Junker H, Kimura A, Lanata CF,
Lehmann C, Leroux-Roels I, Mann P, Martinez-Reséndez MF, Ochoa TJ, Poy CA, Reyes
Fentanes MJ, Rivera Mejia LM, Ruiz Herrera VV, Sáez-Llorens X, Schönborn-Kellenberger
O, Schunk M, Sierra Garcia A, Vergara I, Verstraeten T, Vico M, Oostvogels L, Lovesio L,
Diez F, Grazziani F, Ganaha MC, Zalatnik VJ, Dittrich RJ, Espínola L, Lambert S, Longhi
A, Vecchio C, Mastruzzo M, Fernandez A, Borchowiek S, Potito R, Ahuad Guerrero RA,
Guardiani FM, Castella S, Foccoli M, Pedernera A, Braida A, Durigan V, Martella C, Bobat
A, Boggia BE, Nemi SA, Tartaglione JG, Piedimonte FC, De Bie J, Reynales Londoño H,
Rodríguez Ordoñez PA, García Cruz JM, Bautista Toloza L, Ladino González MC, Zambrano
Ochoa AP, Prieto Pradera I, Torres Hernandez D, Mazo Elorza DP, Collazos Lennis MF,
Vanegas Dominguez B, Solano Mosquera LM, Fendel R, Fleischmann WA, Koehne E,
Kreidenweiss A, Köhler C, Esen M, Horn C, Eberts S, Kroidl A, Huber K, Thiel V, Mazara
Rosario S, Reyes G, Rivera L, Donastorg Y, Lantigua F, Torres Almanzar D, Candelario R,
Peña Mendez L, Rosario Gomez N, Portolés-Pérez A, Ascaso del Río A, Laredo Velasco L,
Bustinduy Odriozola MJ, Larrea Arranz I, Martínez Alcorta LI, Durán Laviña MI, ImazAyo N, Meijide S, García-de-Vicuña A, Santorcuato A, Gallego M, Aguirre-García GM,
Olmos Vega J, González Limón P, Vázquez Villar A, Chávez Barón J, Arredondo Saldaña
F, Luján Palacios JD, Camacho Choza LJ, Vázquez Saldaña EG, Ortega Dominguez SJ,
Vega Orozco KS, Torres Quiroz IA, Martinez Avendaño A, Herrera Sanchez J, Guzman E,
Castro Castrezana L, Ruiz Palacios y Santos GM, de Winter RFJ, de Jonge HK, Schnyder JL,
Boersma W, Hessels L, Djamin R, van der Sar S, DeAntonio R, Peña M, Rebollon G, Rojas
M, Escobar J, Hammerschlag Icaza B, Wong TDY, Barrera Perigault P, Ruiz S, Chan M, Arias
Hoo DJ, Gil AI, Celis CR, Balmaceda MP, Flores O, Ochoa M, Peña B, de la Flor C, Webb
CM, Cornejo E, Sanes F, Mayorga V, Valdiviezo G, Ramírez Lamas SP, Grandez Castillo
GA, Lama JR, Matta Aguirre ME, Arancibia Luna LA, Carbajal Paulet Ó, Zambrano Ortiz
J, Camara A, Guzman Quintanilla F, Diaz-Parra C, Morales-Oliva J, Cornejo RE, Ricalde
SA, Vidal J, Rios Nogales L, Cheatham-Seitz D, Gregoraci G, Brecx A, Walz L, Vahrenhorst
D, Seibel T, Quintini G (2022) Efcacy and safety of the CVnCoV SARS-CoV-2 mRNA
vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised,
observer-blinded, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis 22:329–340. https://
doi.org/10.1016/S1473- 3099(21)00677- 0
50. Gebre MS, Rauch S, Roth N, Yu J, Chandrashekar A, Mercado NB, He X, Liu J, McMahan K,
Martinot A, Martinez DR, Gifn V, Hope D, Patel S, Sellers D, Sanborn O, Barrett J, Liu X,
Cole AC, Pessaint L, Valentin D, Flinchbaugh Z, Yalley-Ogunro J, Muench J, Brown R, Cook
A, Teow E, Andersen H, Lewis MG, Boon ACM, Baric RS, Mueller SO, Petsch B, Barouch
DH (2021) Optimization of non-coding regions for a non-modied mRNA COVID-19 vaccine. Nature. https://doi.org/10.1038/s41586- 021- 04231- 6
51. Andries O, Mc Cafferty S, De Smedt SC, Weiss R, Sanders NN, Kitada T (2015) N(1)methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA
by providing enhanced protein expression and reduced immunogenicity in mammalian cell
lines and mice. J Control Release 217:337–344. https://doi.org/10.1016/j.jconrel.2015.08.051
211
212
52. Svitkin YV, Cheng YM, Chakraborty T, Presnyak V, John M, Sonenberg N (2017)
N1-methyl- pseudouridine in mRNA enhances translation through eIF2α-dependent
and independent mechanisms by increasing ribosome density. Nucleic Acids Res
45:6023–6036. https://doi.org/10.1093/nar/gkx135
53. Anderson BR, Muramatsu H, Jha BK, Silverman RH, Weissman D, Karikó K (2011)
Nucleoside modications in RNA limit activation of 2′-5′-oligoadenylate synthetase and
increase resistance to cleavage by RNase L.Nucleic Acids Res 39:9329–9338. https://doi.
org/10.1093/nar/gkr586
54. Bloom K, van den Berg F, Arbuthnot P (2021) Self-amplifying RNA vaccines for infectious
diseases. Gene Ther 28:117–129. https://doi.org/10.1038/s41434- 020- 00204- y
55. de Alwis R, Gan ES, Chen S, Leong YS, Tan HC, Zhang SL, Yau C, Low JGH, Kalimuddin
S, Matsuda D, Allen EC, Hartman P, Park K-JJ, Alayyoubi M, Bhaskaran H, Dukanovic A,
Bao Y, Clemente B, Vega J, Roberts S, Gonzalez JA, Sablad M, Yelin R, Taylor W, Tachikawa
K, Parker S, Karmali P, Davis J, Sullivan BM, Sullivan SM, Hughes SG, Chivukula P, Ooi
EE (2021) A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice. Mol Ther 29:1970–1983. https://doi.
org/10.1016/j.ymthe.2021.04.001
56. Pardi N, Muramatsu H, Weissman D, Karikó K (2013) In vitro transcription of long RNA
containing modied nucleosides. In: Rabinovich PM (ed) Synthetic messenger RNA and cell
metabolism modulation: methods and protocols. Humana Press, Totowa, pp29–42
57. Beckert B, Masquida B (2011) Synthesis of RNA by invitro transcription. In: Nielsen H (ed)
RNA: methods and protocols. Humana Press, Totowa, pp29–41
58. Vaidyanathan S, Azizian KT, Haque AKMA, Henderson JM, Hendel A, Shore S, Antony
JS, Hogrefe RI, Kormann MSD, Porteus MH, McCaffrey AP (2018) Uridine depletion and
chemical modication increase Cas9 mRNA activity and reduce immunogenicity without HPLC purication. Mol Ther Nucleic Acids 12:530–542. https://doi.org/10.1016/j.
omtn.2018.06.010
59. Martin SA, Paoletti E, Moss B (1975) Purication of mRNA guanylyltransferase and mRNA
(guanine-7-) methyltransferase from vaccinia virions. J Biol Chem 250:9322–9329. https://
doi.org/10.1016/S0021- 9258(19)40646- 7
60. Shuman S (1990) Catalytic activity of vaccinia mRNA capping enzyme subunits coexpressed in Escherichia coli. J Biol Chem 265:11960–11966. https://doi.org/10.1016/
S0021- 9258(19)38494- 7
61. Bélanger F, Stepinski J, Darzynkiewicz E, Pelletier J (2010) Characterization of hMTr1,
a human Cap1 2′-O-ribose methyltransferase. J Biol Chem 285:33037–33044. https://doi.
org/10.1074/jbc.M110.155283
62. Pourseif MM, Masoudi-Sobhanzadeh Y, Azari E, Parvizpour S, Barar J, Ansari R, Omidi Y
(2022) Self-amplifying mRNA vaccines: mode of action, design, development and optimization. Drug Discov Today 27:103341. https://doi.org/10.1016/j.drudis.2022.103341
63. Goey CH, Alhuthali S, Kontoravdi C (2018) Host cell protein removal from biopharmaceutical preparations: towards the implementation of quality by design. Biotechnol Adv
36:1223–1237. https://doi.org/10.1016/j.biotechadv.2018.03.021
64. Liu MA (2019) A comparison of plasmid DNA and mRNA as vaccine technologies.
Vaccine 7:37
65. Henderson JM, Ujita A, Hill E, Yousif-Rosales S, Smith C, Ko N, McReynolds T, Cabral
CR, Escamilla-Powers JR, Houston ME (2021) Cap 1 messenger RNA synthesis with cotranscriptional CleanCap® analog by invitro transcription. Curr Protoc 1:e39. https://doi.
org/10.1002/cpz1.39
66. Rosa SS, Prazeres DMF, Azevedo AM, Marques MPC (2021) mRNA vaccines manufacturing: challenges and bottlenecks. Vaccine 39:2190–2200. https://doi.org/10.1016/j.
vaccine.2021.03.038
J. A. S. Romine etal.
8 COVID-19 Vaccine Manufacturing Processes: Making the Molecules to Solve…
67. Rio DC, Ares M, Hannon GJ, Nilsen TW (2010) Enrichment of poly(A)+ mRNA using immobilized oligo (dT). Cold Spring Harb Protoc 2010:pdb.prot5454. https://doi.org/10.1101/pdb.
prot5454
68. Shen CF, Jacob D, Zhu T, Bernier A, Shao Z, Yu X, Patel M, Lanthier S, Kamen A (2016)
Optimization and scale-up of cell culture and purication processes for production of an
adenovirus-vectored tuberculosis vaccine candidate. Vaccine 34:3381–3387. https://doi.
org/10.1016/j.vaccine.2016.04.090
69. Abbink P, Lemckert AAC, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen
I, Vogels R, Thorner AR, O’Brien KL, Carville A, Manseld KG, Goudsmit J, Havenga MJE,
Barouch DH (2007) Comparative seroprevalence and immunogenicity of six rare serotype
recombinant adenovirus vaccine vectors from subgroups B and D.J Virol 81:4654–4663.
https://doi.org/10.1128/JVI.02696- 06
70. Afolabi MO, Tiono AB, Adetifa UJ, Yaro JB, Drammeh A, Nébié I, Bliss C, Hodgson SH,
Anagnostou NA, Sanou GS, Jagne YJ, Ouedraogo O, Tamara C, Ouedraogo N, Ouedraogo
M, Njie-Jobe J, Diarra A, Duncan CJA, Cortese R, Nicosia A, Roberts R, Viebig NK, Leroy
O, Lawrie AM, Flanagan KL, Kampman B, Bejon P, Imoukhuede EB, Ewer KJ, Hill AVS,
Bojang K, Sirima SB (2016) Safety and immunogenicity of ChAd63 and MVA ME-TRAP
in West African children and infants. Mol Ther 24:1470–1477. https://doi.org/10.1038/
mt.2016.83
71. Custers J, Kim D, Leyssen M, Gurwith M, Tomaka F, Robertson J, Heijnen E, Condit R,
Shukarev G, Heerwegh D, van Heesbeen R, Schuitemaker H, Douoguih M, Evans E, Smith
ER, Chen RT (2021) Vaccines based on replication incompetent Ad26 viral vectors: standardized template with key considerations for a risk/benet assessment. Vaccine 39:3081–3101.
https://doi.org/10.1016/j.vaccine.2020.09.018
72. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D,
Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath
P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson
H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC,
Pollard AJ, Aboagye J, Adams K, Ali A, Allen E, Allison JL, Anslow R, Arbe-Barnes EH,
Babbage G, Baillie K, Baker M, Baker N, Baker P, Baleanu I, Ballaminut J, Barnes E,
Barrett J, Bates L, Batten A, Beadon K, Beckley R, Berrie E, Berry L, Beveridge A, Bewley
KR, Bijker EM, Bingham T, Blackwell L, Blundell CL, Bolam E, Boland E, Borthwick N,
Bower T, Boyd A, Brenner T, Bright PD, Brown-O’Sullivan C, Brunt E, Burbage J, Burge
S, Buttigieg KR, Byard N, Cabera Puig I, Calvert A, Camara S, Cao M, Cappuccini F, Carr
M, Carroll MW, Carter V, Cathie K, Challis RJ, Charlton S, Chelysheva I, Cho J-S, Cicconi
P, Cifuentes L, Clark H, Clark E, Cole T, Colin-Jones R, Conlon CP, Cook A, Coombes NS,
Cooper R, Cosgrove CA, Coy K, Crocker WEM, Cunningham CJ, Damratoski BE, Dando
L, Datoo MS, Davies H, De Graaf H, Demissie T, Di Maso C, Dietrich I, Dong T, Donnellan
FR, Douglas N, Downing C, Drake J, Drake-Brockman R, Drury RE, Dunachie SJ, Edwards
NJ, Edwards FDL, Edwards CJ, Elias SC, Elmore MJ, Emary KRW, English MR, Fagerbrink
S, Felle S, Feng S, Field S, Fixmer C, Fletcher C, Ford KJ, Fowler J, Fox P, Francis E, Frater
J, Furze J, Fuskova M, Galiza E, Gbesemete D, Gilbride C, Godwin K, Gorini G, Goulston
L, Grabau C, Gracie L, Gray Z, Guthrie LB, Hackett M, Halwe S, Hamilton E, Hamlyn J,
Hanumunthadu B, Harding I, Harris SA, Harris A, Harrison D, Harrison C, Hart TC, Haskell
L, Hawkins S, Head I, Henry JA, Hill J, Hodgson SHC, Hou MM, Howe E, Howell N, Hutlin
C, Ikram S, Isitt C, Iveson P, Jackson S, Jackson F, James SW, Jenkins M, Jones E, Jones K,
Jones CE, Jones B, Kailath R, Karampatsas K, Keen J, Kelly S, Kelly D, Kerr D, Kerridge S,
Khan L, Khan U, Killen A, Kinch J, King TB, King L, King J, Kingham-Page L, Klenerman
P, Knapper F, Knight JC, Knott D, Koleva S, Kupke A, Larkworthy CW, Larwood JPJ, Laskey
A, Lawrie AM, Lee A, Ngan Lee KY, Lees EA, Legge H, Lelliott A, Lemm N-M, Lias AM,
Linder A, Lipworth S, Liu X, Liu S, Lopez Ramon R, Lwin M, Mabesa F, Madhavan M,
Mallett G, Mansatta K, Marcal I, Marinou S, Marlow E, Marshall JL, Martin J, McEwan J,
McInroy L, Meddaugh G, Mentzer AJ, Mirtorabi N, Moore M, Moran E, Morey E, Morgan
213
214
V, Morris SJ, Morrison H, Morshead G, Morter R, Mujadidi YF, Muller J, Munera-Huertas T,
Munro C, Munro A, Murphy S, Munster VJ, Mweu P, Noé A, Nugent FL, Nuthall E, O’Brien
K, O’Connor D, Oguti B, Oliver JL, Oliveira C, O’Reilly PJ, Osborn M, Osborne P, Owen
C, Owens D, Owino N, Pacurar M, Parker K, Parracho H, Patrick-Smith M, Payne V, Pearce
J, Peng Y, Peralta Alvarez MP, Perring J, Pfafferott K, Pipini D, Plested E, Pluess-Hall H,
Pollock K, Poulton I, Presland L, Provstgaard-Morys S, Pulido D, Radia K, Ramos Lopez
F, Rand J, Ratcliffe H, Rawlinson T, Rhead S, Riddell A, Ritchie AJ, Roberts H, Robson
J, Roche S, Rohde C, Rollier CS, Romani R, Rudiansyah I, Saich S, Sajjad S, Salvador
S, Sanchez Riera L, Sanders H, Sanders K, Sapaun S, Sayce C, Schoeld E, Screaton G,
Selby B, Semple C, Sharpe HR, Shaik I, Shea A, Shelton H, Silk S, Silva-Reyes L, Skelly
DT, Smee H, Smith CC, Smith DJ, Song R, Spencer AJ, Stafford E, Steele A, Stefanova E,
Stockdale L, Szigeti A, Tahiri-Alaoui A, Tait M, Talbot H, Tanner R, Taylor IJ, Taylor V,
Te Water Naude R, Thakur N, Themistocleous Y, Themistocleous A, Thomas M, Thomas
TM, Thompson A, Thomson-Hill S, Tomlins J, Tonks S, Towner J, Tran N, Tree JA, Truby
A, Turkentine K, Turner C, Turner N, Turner S, Tuthill T, Ulaszewska M, Varughese R, Van
Doremalen N, Veighey K, Verheul MK, Vichos I, Vitale E, Walker L, Watson MEE, Welham
B, Wheat J, White C, White R, Worth AT, Wright D, Wright S, Yao XL, Yau Y (2020) Safety
and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary
report of a phase 1/2, single-blind, randomised controlled trial. Lancet 396:467–478. https://
doi.org/10.1016/S0140- 6736(20)31604- 4
73. Shabram P, Vellekamp G, Scandella C (2002) Chapter 7– Purication of adenovirus. In:
Curiel DT, Douglas JT (eds) Adenoviral vectors for gene therapy. Academic Press, San
Diego, pp167–203
74. Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJM, Hehir KM, Keegan J,
Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, Valerio D, Hoeben RC (1998) New
helper cells and matched early region 1-deleted adenovirus vectors prevent generation of
replication-competent adenoviruses. Hum Gene Ther 9:1909–1917. https://doi.org/10.1089/
hum.1998.9.13- 1909
75. Graham FL, Smiley J, Russell WC, Nairn R (1977) Characteristics of a human cell line
transformed by DNA from human adenovirus type 5. J Gen Virol 36:59–72. https://doi.org/1
0.1099/0022- 1317- 36- 1- 59
76. Joe CCD, Jiang J, Linke T, Li Y, Fedosyuk S, Gupta G, Berg A, Segireddy RR, Mainwaring
D, Joshi A, Cashen P, Rees B, Chopra N, Nestola P, Humphreys J, Davies S, Smith N, Bruce
S, Verbart D, Bormans D, Knevelman C, Woodyer M, Davies L, Cooper L, Kapanidou M,
Bleckwenn N, Pappas D, Lambe T, Smith DC, Green CM, Venkat R, Ritchie AJ, Gilbert
SC, Turner R, Douglas AD (2022) Manufacturing a chimpanzee adenovirus-vectored SARSCoV- 2 vaccine to meet global needs. Biotechnol Bioeng 119:48–58. https://doi.org/10.1002/
bit.27945
77. Schwarz H, Zhang Y, Zhan C, Malm M, Field R, Turner R, Sellick C, Varley P, Rockberg
J, Chotteau V (2020) Small-scale bioreactor supports high density HEK293 cell perfusion
culture for the production of recombinant Erythropoietin. J Biotechnol 309:44–52. https://
doi.org/10.1016/j.jbiotec.2019.12.017
78. Kamen A, Henry O (2004) Development and optimization of an adenovirus production process. J Gene Med 6:S184–S192. https://doi.org/10.1002/jgm.503
79. Vellinga J, Smith JP, Lipiec A, Majhen D, Lemckert A, van Ooij M, Ives P, Yallop C, Custers
J, Havenga M (2014) Challenges in manufacturing adenoviral vectors for global vaccine
product deployment. Hum Gene Ther 25:318–327. https://doi.org/10.1089/hum.2014.007
80. Luitgens A, Lewis JA (2018) Method for the production of adenoviral vaccines. In: Ofce
USP (ed) Janssen Vaccines and Prevention B.V., United States
81. Moleirinho GM, Rosa S, Carrondo JTM, Silva JSR, Hagner-McWhirter Å, Ahlén G,
Lundgren M, Alves MP, Peixoto C (2018) Clinical-grade oncolytic adenovirus purication
using polysorbate 20 as an alternative for cell lysis. Curr Gene Ther 18:366–374. https://doi.
org/10.2174/1566523218666181109141257
J. A. S. Romine etal.
8 COVID-19 Vaccine Manufacturing Processes: Making the Molecules to Solve…
82. Klyushnichenko V, Bernier A, Kamen A, Harmsen E (2001) Improved high-performance liquid chromatographic method in the analysis of adenovirus particles. J Chromatogr B Biomed
Sci Appl 755:27–36. https://doi.org/10.1016/S0378- 4347(00)00597- 1
83. Riske F, Berard N, Albee K, Pan P, Henderson M, Adams K, Godwin S, Spear S (2013)
Development of a platform process for adenovirus purication that removes human set and
nucleolin and provides high purity vector for gene delivery. Biotechnol Bioeng 110:848–856.
https://doi.org/10.1002/bit.24742
84. Altaras NE, Aunins JG, Evans RK, Kamen A, Konz JO, Wolf JJ (2005) Production and formulation of adenovirus vectors. In: Gene therapy and gene delivery systems. Springer Berlin
Heidelberg, Berlin, Heidelberg, pp193–260
85. Zimmer C, Corum J, Wee S, Kristoffersen M (2022) Coronavirus Vaccine Tracker. The
New York Times. https://www.nytimes.com/interactive/2020/science/coronavirusvaccine-
tracker.html
86. Wang Y, Yang C, Song Y, Coleman JR, Stawowczyk M, Tafrova J, Tasker S, Boltz D, Baker
R, Garcia L, Seale O, Kushnir A, Wimmer E, Mueller S (2021) Scalable live-attenuated
SARS- CoV- 2 vaccine candidate demonstrates preclinical safety and efcacy. Proc Natl
Acad Sci 118:e2102775118. https://doi.org/10.1073/pnas.2102775118
87. Wang Z-J, Zhang H-J, Lu J, Xu K-W, Peng C, Guo J, Gao X-X, Wan X, Wang W-H, Shan C,
Zhang S-C, Wu J, Yang A-N, Zhu Y, Xiao A, Zhang L, Fu L, Si H-R, Cai Q, Yang X-L, You L,
Zhou Y-P, Liu J, Pang D-Q, Jin W-P, Zhang X-Y, Meng S-L, Sun Y-X, Desselberger U, Wang
J-Z, Li X-G, Duan K, Li C-G, Xu M, Shi Z-L, Yuan Z-M, Yang X-M, Shen S (2020) Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19in different animal models. Emerg Microbes Infect 9:2606–2618. https://doi.org/10.1080/2222175
1.2020.1852059
88. Barrett PN, Mundt W, Kistner O, Howard MK (2009) Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines 8:607–618.
https://doi.org/10.1586/erv.09.19
89. Sène M-A, Xia Y, Kamen AA (2022) Overview of recent advances in Vero cells genomic
characterization and engineering for high-throughput vaccine manufacturing. Clin Transl
Discov 2:e40. https://doi.org/10.1002/ctd2.40
90. Kiesslich S, Kamen AA (2020) Vero cell upstream bioprocess development for the production of viral vectors and vaccines. Biotechnol Adv 44:107608. https://doi.org/10.1016/j.
biotechadv.2020.107608
91. Kiesslich S, Kim GN, Shen CF, Kang CY, Kamen AA (2021) Bioreactor production of rVSVbased vectors in Vero cell suspension cultures. Biotechnol Bioeng 118:2649–2659. https://
doi.org/10.1002/bit.27785
92. LoGrippo GA, Hartman FW (1955) Antigenicity of β-propiolactone-inactivated virus vaccines. J Immunol 75:123–128
93. Uittenbogaard JP, Zomer B, Hoogerhout P, Metz B (2011) Reactions of β-propiolactone with
nucleobase analogues, nucleosides, and peptides: implications for the inactivation of viruses.
J Biol Chem 286:36198–36214. https://doi.org/10.1074/jbc.M111.279232
94. Hemminki K (1981) Reactions of β-propiolactone, β-butyrolactone and γ-butyrolactone with
nucleic acids. Chem Biol Interact 34:323–331. https://doi.org/10.1016/0009- 2797(81)90104- 6
95. Patterson EI, Prince T, Anderson ER, Casas-Sanchez A, Smith SL, Cansado-Utrilla C,
Solomon T, Grifths MJ, Acosta-Serrano Á, Turtle L, Hughes GL (2020) Methods of inactivation of SARS-CoV-2 for downstream biological assays. J Infect Dis 222:1462–1467.
https://doi.org/10.1093/infdis/jiaa507
96. Pollet J, Chen W-H, Strych U (2021) Recombinant protein vaccines, a proven approach
against coronavirus pandemics. Adv Drug Deliv Rev 170:71–82. https://doi.org/10.1016/j.
addr.2021.01.001
97. Sunasara K, Cundy J, Srinivasan S, Evans B, Sun W, Cook S, Bortell E, Farley J, Grifn D,
Bailey Piatchek M, Arch-Douglas K (2018) Bivalent rLP2086 (Trumenba®): development of
215
216
a well-characterized vaccine through commercialization. Vaccine 36:3180–3189. https://doi.
org/10.1016/j.vaccine.2017.03.100
98. Comstedt P, Schüler W, Meinke A, Lundberg U (2017) The novel Lyme borreliosis vaccine
VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes. PLoS One 12:e0184357. https://doi.org/10.1371/journal.pone.0184357
99. Phillips A, Patel C, Pillsbury A, Brotherton J, Macartney K (2018) Safety of human papillomavirus vaccines: an updated review. Drug Saf 41:329–346. https://doi.org/10.1007/
s40264- 017- 0625- z
100. Gräslund S, Nordlund P, Weigelt J, Hallberg BM, Bray J, Gileadi O, Knapp S, Oppermann
U, Arrowsmith C, Hui R, Ming J, dhe-Paganon S, Park H-W, Savchenko A, Yee A, Edwards
A, Vincentelli R, Cambillau C, Kim R, Kim S-H, Rao Z, Shi Y, Terwilliger TC, Kim C-Y,
Hung L-W, Waldo GS, Peleg Y, Albeck S, Unger T, Dym O, Prilusky J, Sussman JL, Stevens
RC, Lesley SA, Wilson IA, Joachimiak A, Collart F, Dementieva I, Donnelly MI, Eschenfeldt
WH, Kim Y, Stols L, Wu R, Zhou M, Burley SK, Emtage JS, Sauder JM, Thompson D,
Bain K, Luz J, Gheyi T, Zhang F, Atwell S, Almo SC, Bonanno JB, Fiser A, Swaminathan
S, Studier FW, Chance MR, Sali A, Acton TB, Xiao R, Zhao L, Ma LC, Hunt JF, Tong
L, Cunningham K, Inouye M, Anderson S, Janjua H, Shastry R, Ho CK, Wang D, Wang
H, Jiang M, Montelione GT, Stuart DI, Owens RJ, Daenke S, Schütz A, Heinemann U,
Yokoyama S, Büssow K, Gunsalus KC, Structural Genomics C, Architecture et Fonction
des Macromolécules B, Berkeley Structural Genomics C, China Structural Genomics C,
Integrated Center for S, Function I, Israel Structural Proteomics C, Joint Center for Structural
G, Midwest Center for Structural G, New York Structural Genomi XRCfSG, Northeast
Structural Genomics C, Oxford Protein Production F, Protein Sample Production Facility
MDCfMM, Initiative RSGP and Complexes S (2008) Protein production and purication.
Nat Methods 5:135–146. https://doi.org/10.1038/nmeth.f.202
101. Tripathi NK, Shrivastava A (2019) Recent developments in bioprocessing of recombinant
proteins: expression hosts and process development. Front Bioeng Biotechnol 7. https://doi.
org/10.3389/fbioe.2019.00420
102. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D (2020) Structure, function,
and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181:281–292.e6. https://doi.
org/10.1016/j.cell.2020.02.058
103. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, Graham BS, McLellan
JS (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science
(New York, NY) 367:1260–1263. https://doi.org/10.1126/science.abb2507
104. Wang Q, Zhang L, Kuwahara K, Li L, Liu Z, Li T, Zhu H, Liu J, Xu Y, Xie J, Morioka H,
Sakaguchi N, Qin C, Liu G (2016) Immunodominant SARS coronavirus epitopes in humans
elicited both enhancing and neutralizing effects on infection in non-human primates. ACS
Infect Dis 2:361–376. https://doi.org/10.1021/acsinfecdis.6b00006
105. D’Aoust M-A, Couture MM-J, Charland N, Trépanier S, Landry N, Ors F, Vézina L-P
(2010) The production of hemagglutinin-based virus-like particles in plants: a rapid, efcient and safe response to pandemic inuenza. Plant Biotechnol J 8:607–619. https://doi.
org/10.1111/j.1467- 7652.2009.00496.x
106. Amblard M, Fehrentz J-A, Martinez J, Subra G (2006) Methods and protocols of modern solid
phase peptide synthesis. Mol Biotechnol 33:239–254. https://doi.org/10.1385/MB:33:3:239
107. Palomo JM (2014) Solid-phase peptide synthesis: an overview focused on the preparation of biologically relevant peptides. RSC Adv 4:32658–32672. https://doi.org/10.1039/
C4RA02458C
108. Valdes-Balbin Y, Santana-Mederos D, Quintero L, Fernández S, Rodriguez L, Sanchez
Ramirez B, Perez-Nicado R, Acosta C, Méndez Y, Ricardo MG, Hernandez T, Bergado G,
Pi F, Valdes A, Carmenate T, Ramirez U, Oliva R, Soubal J-P, Garrido R, Cardoso F, Landys
M, Gonzalez H, Farinas M, Enriquez J, Noa E, Suarez A, Fang C, Espinosa LA, Ramos
Y, González LJ, Climent Y, Rojas G, Relova-Hernández E, Cabrera Infante Y, Losada SL,
Boggiano T, Ojito E, León K, Chiodo F, Paquet F, Chen G-W, Rivera DG, Garcia-Rivera D,
J. A. S. Romine etal.
8 COVID-19 Vaccine Manufacturing Processes: Making the Molecules to Solve…
Verez Bencomo V (2021) SARS-CoV-2 RBD-tetanus toxoid conjugate vaccine induces a
strong neutralizing immunity in preclinical studies. ACS Chem Biol 16:1223–1233. https://
doi.org/10.1021/acschembio.1c00272
109. van der Put RMF, Kim TH, Guerreiro C, Thouron F, Hoogerhout P, Sansonetti PJ, Westdijk
J, Stork M, Phalipon A, Mulard LA (2016) A synthetic carbohydrate conjugate vaccine candidate against shigellosis: improved bioconjugation and impact of alum on immunogenicity.
Bioconjug Chem 27:883–892. https://doi.org/10.1021/acs.bioconjchem.5b00617
110. Dalal J, Rana R, Harale K, Hanif S, Kumar N, Singh D, Chhikara MK (2019) Development
and pre-clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against
Neisseria meningitidis serogroup C. Vaccine 37:5297–5306. https://doi.org/10.1016/j.
vaccine.2019.07.053
111. Prasad AK, Kim J-H, Gu J (2018) Design and development of glycoconjugate vaccines. In:
Carbohydrate-based vaccines: from concept to clinic. American Chemical Society, pp75–100
112. Prasad AK, Murphy K, Kolodziej SA (2018) Manufacturing considerations for glycoconjugate vaccines. In: Carbohydrate-based vaccines: from concept to clinic. American Chemical
Society, pp101–122
217
Part V
Special Topics: CAR-T and CRISPR
Technologies and Applications